Global University Venturing

Chuck Vallurupalli and Preeti Chalsani will serve as senior director and deputy director, respectively, of the quantum accelerator.

The oncology therapeutics developer has added $66m to its coffers thanks to investors including Berkeley Catalyst Fund.

Flagship Pioneering has re-opened its Fund VII to raise an additional $2.23bn that brought the vehicle’s total capital to $3.37bn.

The Industrial Biotechnology Innovation Centre will invest in research projects at Scottish universities to support the creation of more spinouts.

Alexandria Venture Investments was among the participants in a series A for the cellular cancer therapeutics developer based on work at Institut Curie and Memorial Sloan Kettering.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

Motif FoodWorks, which traces its roots to MIT, has pocketed $226m in a round backed by returning investor Louis Dreyfus a month after Motif’s parent agreed to a reverse merger.

UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.

Maryland Momentum Fund and VTC Innovation Fund have both contributed to a series A round for Veralox Therapeutics, which is focusing on diseases with unmet needs.